6S Pharma

6S Pharma is an early-stage, private biotech startup employing a dual-strategy business model centered on 505(b)(2) drug repurposing and complex generic development. The company is preparing to file IND applications for two of its 505(b)(2) products and advance them into human proof-of-concept studies, while also planning ANDA filings for complex generics by the end of 2024. With a pipeline targeting indications with substantial market opportunities (each exceeding $2 billion) and an experienced leadership team with FDA and global development expertise, 6S aims to create a dynamic portfolio that balances innovation with rapid revenue potential.

Expertise in the 505(b)(2) regulatory pathway for drug repurposing and formulation science for developing complex generics. The platform focuses on applying novel formulations and clinical development strategies to approved drugs to create new, value-added therapies.

6S Pharma competes with other biotechs specializing in drug repurposing via the 505(b)(2) pathway, as well as established generics companies with complex product capabilities. Its differentiation lies in its hybrid model, combining innovative repurposing with complex generic development under one roof, and its leadership's deep FDA and clinical development experience.